2011 PCNA Fall Lecture Series
REGISTER HERE
FAQs
TOPICS:
The Use of Biomarkers in the Assessment of CVD Risk: 2011 Update
Familial Hypercholesterolemia: Identification and Optimal Treatment
Management of Dyslipidemia in Patients with Chronic Kidney Disease
CONTINUING EDUCATION:
RN, NP: 2.25 CE Credits (1 hour of pharmacology)
Date: Saturday, November 5, 2011
Times: 9:00 am – 12:00 pm EDT
8:00am – 11:00 am CDT
7:00 am – 10:00 am MDT
6:00 am – 9:00 am PDT
COURSE OVERVIEW:
Join us for the online broadcast of the 2011 PCNA Fall Lecture Series, live from Charlottesville, VA. Expert speakers will provide the latest information regarding biomarkers in the assessment of CVD risk, familial hypercholesterolemia and managing dyslipidemia in patients with CKD. All professional disciplines, PCNA members and non-members are welcome to register for FREE!
EDUCATIONAL OBJECTIVES:
Upon completion of this program, participants will be able to:
The Use of Biomarkers in the Assessment of CVD Risk: 2011 Update
- Distinguish between a risk factor and a risk marker
- Define the term incremental risk
- List 3 mechanisms by which biomarker measurement may improve health outcomes
Familial Hyperlipidemia: Identification and Optimal Treatment
- Describe the prevalence of Familial Hyperlipidemia (FH)
- Identify the familial disorders and clinical features/diagnostic criteria
- Discuss current therapeutic approaches and outcomes
Management of Dyslipidemia in Patients with Chronic Kidney Disease
- Identify common lipid abnormalities seen in patients with chronic kidney disease (CKD)
- Review the study evidence for use of statin therapy in patients with kidney disease
- Cite the need for close follow-up and careful titration of dyslipidemic agents in patients with CKD
AUDIENCE:
Nurses, nurse practitioners, and other healthcare professionals interested in the prevention and management of cardiovascular disease.
PROGRAM SPEAKERS:
Kenneth S. Sternberg, DO, FACC
Blue Ridge Heart & Vascular
Charlottesville, VA
Helen-Marie Molnar, MSN, RN, ACNP-BC, FNP-BC
University of Virginia Cardiology Prevention Clinic
Charlottesville, VA
3rd Speaker TBD
COURSE EDITORS:
Tony Farah, MD, FSCAI
Chief Medical Officer, Medical Director
Cardiac Catheterization Laboratories, Allegheny General Hospital
Pittsburgh, PA
Suzanne Hughes, RN, MSN, FAHA, FPCNA
Director, Population Health
Summa Health System
Akron, OH
Cindy Lamendola, MSN, ANP-BC, FAHA, FPCNA
Nurse Practitioner/Clinical Research Nurse Coordinator
Stanford University School of Medicine
Stanford, CA
FACULTY DISCLOSURES:
The Course Editors have declared no commercial relationships related to the content of this presentation.
COST:
This educational activity is offered free of charge.
PARTICIPATION IN THE ACTIVITY AND RECEIPT OF CERTIFICATE OF CREDIT:
View the program materials, complete the online evaluation at the end of the activity, and print your CE certificate.
ACCREDITOR:
This activity is sponsored by the Preventive Cardiovascular Nurses Association (PCNA). PCNA is accredited by the American Academy of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030602. This program is accredited for 2.25 contact hours of continuing education (1 hour of pharmacology). This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards
GRANTOR:
This continuing education activity is supported by educational grants from AstraZeneca, Cleveland Heart Lab, diaDexus, Inc., Genzyme, Inc. and Merck & Co., Inc.
TECHNICAL SUPPORT/REQUIREMENTS:
Refer to the Technical Support document for assistance or send an email to pcna@commpartners.com.
REGISTER HERE
FAQs
BACK TO MAIN PAGE | 